Charles A. Conrad

7.9k total citations · 1 hit paper
87 papers, 5.0k citations indexed

About

Charles A. Conrad is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Charles A. Conrad has authored 87 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 39 papers in Genetics and 35 papers in Oncology. Recurrent topics in Charles A. Conrad's work include Glioma Diagnosis and Treatment (39 papers), Brain Metastases and Treatment (16 papers) and Cancer, Hypoxia, and Metabolism (11 papers). Charles A. Conrad is often cited by papers focused on Glioma Diagnosis and Treatment (39 papers), Brain Metastases and Treatment (16 papers) and Cancer, Hypoxia, and Metabolism (11 papers). Charles A. Conrad collaborates with scholars based in United States, Spain and Switzerland. Charles A. Conrad's co-authors include Gregory N. Fuller, Tom Peters, Victor A. Levin, Ashok Kumar, Javier Gonzalez, Kenneth R. Hess, John de Groot, Mark R. Gilbert, Amy B. Heimberger and Yang Ji and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Analytical Chemistry.

In The Last Decade

Charles A. Conrad

85 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-L1 expression and prognostic impact in glioblastoma

2015 457 citations Jun Wei, Ling-Yuan Kong et al. Neuro-Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles A. Conrad United States	38	2.0k	1.9k	1.5k	1.1k	879	87	5.0k
John Park United States	37	1.5k 0.8×	1.2k 0.6×	2.0k 1.3×	1.2k 1.1×	620 0.7×	218	7.1k
Frank S. Lieberman United States	38	1.5k 0.7×	2.5k 1.3×	1.6k 1.0×	931 0.9×	844 1.0×	139	5.0k
Susan M. Chang United States	59	2.1k 1.1×	4.5k 2.3×	1.6k 1.0×	1.7k 1.6×	1.1k 1.2×	206	10.2k
Barbara M. Mueller United States	46	2.9k 1.4×	1.2k 0.6×	1.8k 1.2×	595 0.6×	2.1k 2.4×	98	7.9k
Lesley Murray United Kingdom	33	2.2k 1.1×	568 0.3×	1.5k 1.0×	1.1k 1.0×	523 0.6×	94	5.4k
David M. Ashley United States	46	3.4k 1.7×	3.1k 1.6×	2.3k 1.5×	1.2k 1.2×	1.0k 1.1×	236	9.1k
Sylvain Baruchel Canada	42	2.4k 1.2×	742 0.4×	1.6k 1.1×	1.0k 1.0×	1.2k 1.4×	134	5.7k
Nicholas Butowski United States	41	2.0k 1.0×	3.5k 1.8×	1.4k 0.9×	1.3k 1.2×	1.1k 1.3×	188	6.3k
Christopher Calabrese United States	28	2.4k 1.2×	1.3k 0.7×	1.7k 1.1×	334 0.3×	979 1.1×	68	4.9k
Nicholas Lydon Switzerland	29	3.9k 1.9×	4.8k 2.5×	2.7k 1.8×	1.5k 1.4×	719 0.8×	40	12.6k

Countries citing papers authored by Charles A. Conrad

Since Specialization

Citations

This map shows the geographic impact of Charles A. Conrad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles A. Conrad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles A. Conrad more than expected).

Fields of papers citing papers by Charles A. Conrad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles A. Conrad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles A. Conrad. The network helps show where Charles A. Conrad may publish in the future.

Co-authorship network of co-authors of Charles A. Conrad

This figure shows the co-authorship network connecting the top 25 collaborators of Charles A. Conrad. A scholar is included among the top collaborators of Charles A. Conrad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles A. Conrad. Charles A. Conrad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Sun-Jin, Ho Jeong Lee, Hyun Jin Choi, et al.. (2015). Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. Clinical Cancer Research. 21(20). 4630–4641. 50 indexed citations

Liu, Yanhong, Renke Zhou, Erik P. Sulman, et al.. (2015). Genetic Modulation of Neurocognitive Function in Glioma Patients. Clinical Cancer Research. 21(14). 3340–3346. 27 indexed citations

Bankson, James A., Christopher M. Walker, Marc S. Ramirez, et al.. (2015). Kinetic Modeling and Constrained Reconstruction of Hyperpolarized [1-13C]-Pyruvate Offers Improved Metabolic Imaging of Tumors. Cancer Research. 75(22). 4708–4717. 70 indexed citations

Ladha, Harshad, Tushar Pawar, Mark R. Gilbert, et al.. (2015). Wound healing complications in brain tumor patients on Bevacizumab. Journal of Neuro-Oncology. 124(3). 501–506. 13 indexed citations

Kong, Ling-Yuan, Jun Wei, Ali S. Haider, et al.. (2014). Therapeutic targets in subependymoma. Journal of Neuroimmunology. 277(1-2). 168–175. 15 indexed citations

Yust‐Katz, Shlomit, John F. de Groot, Diane Liu, et al.. (2014). Pregnancy and glial brain tumors. Neuro-Oncology. 16(9). 1289–1294. 62 indexed citations

Emmett, Mark R., Roger A. Kroes, Joseph R. Moskal, et al.. (2013). Integrative Biological Analysis For Neuropsychopharmacology. Neuropsychopharmacology. 39(1). 5–23. 13 indexed citations

Fokt, Izabela, Stanisław Skóra, Charles A. Conrad, et al.. (2012). d-Glucose and d-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated d-glucose, d-mannose, and 2-deoxy-d-glucose. Carbohydrate Research. 368. 111–119. 18 indexed citations

Giglio, Pierre, Kenneth R. Hess, Mark R. Gilbert, et al.. (2011). Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 118(14). 3599–3606. 12 indexed citations

10.

Park, Min, Shreyaskumar Patel, Joseph A. Ludwig, et al.. (2011). Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 117(21). 4939–4947. 175 indexed citations

11.

Reardon, David A., Timothy F. Cloughesy, Jeremy N. Rich, et al.. (2011). Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemotherapy and Pharmacology. 69(1). 281–287. 11 indexed citations

12.

Aoki, Hiroshi, Yasuko Kondo, Kenneth Aldape, et al.. (2008). Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy. 4(4). 467–475. 100 indexed citations

13.

Hussain, S. Farzana, Ling-Yuan Kong, Charles A. Conrad, et al.. (2007). A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients. Cancer Research. 67(20). 9630–9636. 246 indexed citations

14.

Conrad, Charles A., et al.. (2007). Phase I clinical pharmacokinetics of RTA 744 (berubicin(B)), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 13-hydroxy metabolite, berubicinol (B-ol). Molecular Cancer Therapeutics. 6. 2 indexed citations

15.

Kuhn, John G., Susan M. Chang, Patrick Y. Wen, et al.. (2007). Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma. Clinical Cancer Research. 13(24). 7401–7406. 60 indexed citations

16.

Groves, Morris D., Vinay K. Puduvalli, Charles A. Conrad, et al.. (2006). Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status. Journal of Neuro-Oncology. 80(1). 83–90. 41 indexed citations

17.

Conrad, Charles A., C. Ryan Miller, Yongjie Ji, et al.. (2005). Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Therapy. 12(3). 284–294. 46 indexed citations

18.

Chang, Susan M., Patrick Y. Wen, Timothy F. Cloughesy, et al.. (2005). Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs. 23(4). 357–361. 308 indexed citations

19.

Conrad, Charles A.. (2001). Chemotherapy for metastatic tumors to the central nervous system. Current Oncology Reports. 3(6). 490–494. 9 indexed citations

20.

Steck, Peter A., J. M. Bruner, Mark A. Pershouse, et al.. (1993). Molecular, genetic, and biologic aspects of primary brain tumors. 45(4). 296–303. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact